Stockscreener 앱 받기
23.01
8.33%
-2.09
시간 외 거래:
22.99
-0.02
-0.09%
Corvus Pharmaceuticals Inc 주식(CRVS)의 최신 뉴스
Corvus Pharmaceuticals (CRVS) Soars 212% on Impressive Eczema Therapy Study - Finviz
Why Corvus Pharmaceuticals (CRVS) Is Up 211.8% After Upsized Equity Raise On Soquelitinib Phase 2 Plans - Yahoo Finance
What's Driving the Market Sentiment Around Corvus Pharmaceuticals Inc? - Sahm
Corvus Pharmaceuticals raises $201.2 million in upsized public offering By Investing.com - Investing.com South Africa
Corvus rally continues as clinical optimism offsets dilution concerns - Mugglehead Magazine
Corvus Pharmaceuticals raises $201.2 million in upsized public offering - Investing.com
Corvus Pharmaceuticals Closes Upsized Public Offering, Raising Approximately $201.2 Million - Quiver Quantitative
Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M - The Manila Times
Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M - GlobeNewswire Inc.
Cantor Fitzgerald reiterates Overweight rating on Corvus Pharmaceuticals stock By Investing.com - Investing.com Canada
Corvus Pharmaceuticals (CRVS) Hits All-Time High on Eczema Trial Results - Finviz
Corvus Pharmaceuticals - The Pharma Letter
Corvus Pharmaceuticals Announces Major Underwritten Public Stock Offering - TipRanks
Corvus Pharmaceuticals Announces Public Offering of Common Stock - TradingView
Corvus Pharmaceuticals Shares New Phase I Soquelitinib Data Showing Strong AD EASI Gains - MarketBeat
Corvus Pharmaceuticals rises 5%, prices $175M stock offering at $22.15 - MSN
10 Stocks Delivering Double-Digit Gains Effortlessly; 4 Are Hitting New Highs - Insider Monkey
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap UpHere's What Happened - MarketBeat
Jefferies raises Corvus Pharmaceuticals stock price target to $42 on strong AD data - Investing.com Canada
Analysts Crow About Potential Of Corvus Pill To Beat Dupixent - Citeline News & Insights
Corvus Pharmaceuticals Prices Upsized Public Stock Offering - Eudaimonia and Co
Corvus Pharmaceuticals stock hits all-time high at 22.22 USD By Investing.com - Investing.com Nigeria
Corvus Pharmaceuticals launches $150 million public offering By Investing.com - Investing.com India
Corvus Pharmaceuticals Prices $175M Upsized Public Offering to Fund Clinical Trials - Intellectia AI
Corvus Pharmaceuticals prices upsized public offering at $22.15 per share - Investing.com
Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock - Yahoo Finance
Corvus Pharmaceuticals Announces Pricing of Upsized Underwritten Public Offering of Common Stock - Quiver Quantitative
Corvus Pharma raises $175M to advance lymphoma and atopic dermatitis trials - Stock Titan
Corvus Pharmaceuticals price target raised to $32 from $15 at Oppenheimer - TipRanks
Corvus Pharmaceuticals: ITK Inhibitor Soquelitinib AD Data Could Be Improved Upon (CRVS) - Seeking Alpha
Corvus Pharmaceuticals stock hits all-time high at 22.22 USD - Investing.com
Smart Money Is Betting Big In CRVS Options - Benzinga
Corvus Pharmaceuticals stock (CRVS) swings as $150M share sale follows eczema-data surge - TechStock²
Corvus Pharmaceuticals slides premarket after unveiling $150M equity raise - MSN
Soquelitinib Data Push Corvus Pharmaceuticals Stock Higher: What You Should Know (CRVS) - Seeking Alpha
Stock Market Today, Jan. 20: Corvus Pharmaceuticals Surges After Positive Phase 1 Eczema Drug Data - AOL.com
Corvus Pharmaceuticals (CRVS) Is Up 229.4% After Strong Soquelitinib Data In Tough Dermatitis Patients - simplywall.st
Corvus Pharmaceuticals stock price target raised to $27 from $11 at H.C. Wainwright - Investing.com Canada
Corvus Pharmaceuticals Stock (CRVS) Opinions on Phase 1 Trial Results - Quiver Quantitative
Corvus Pharmaceuticals stock price target raised to $27 from $11 at H.C. Wainwright By Investing.com - Investing.com Australia
Netflix, Erasca, Kraft Heinz And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Corvus Pharmaceuticals Stock Pre-Market (-5.9%): Announces $150M Public Offering - Trefis
Corvus Pharmaceuticals stock whipsaws: CRVS slides after $150 million offering follows eczema data surge - TechStock²
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Corvus Pharmaceuticals shares fall after announcing $150 million stock offering - Investing.com
Corvus Pharma Commences Public Offering Of $150 Mln Of Shares; Stock Down - Nasdaq
Corvus reports positive phase 1 data for atopic dermatitis drug By Investing.com - Investing.com India
Corvus Pharma stock dips over 6% after-hours following best day ever — what went wrong? - MSN
Corvus Pharmaceuticals Launches $150 Million Public Offering to Fund Clinical Trials - Intellectia AI
Assessing Corvus Pharmaceuticals (CRVS) Valuation After Positive Soquelitinib Phase 1 Atopic Dermatitis Data - Yahoo Finance
Corvus Pharma Stock Dips Over 6% After-Hours Following Best Day Ever — What Went Wrong? - Stocktwits
Oppenheimer raises Corvus Pharmaceuticals stock price target to $32 on AD data - Investing.com
16.87%
0.58%
자본화:
|
볼륨(24시간):